DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Butyrate extends health and lifespan in mice with mitochondrial deficiency
[Data availability] Ileum RNA-sequencing raw data, as well as microbiota 16S rRNA gene sequencing raw data, are publicly available via NCBI with BioProject numbers PRJNA1301342 and PRJNA1291203, respectively., Mitochondrial diseases progressively lead to multisystemic failure with treatment options remaining extremely limited. Here, to investigate strategies that alleviate mitochondrial dysfunction, we first generate a ubiquitous and tamoxifen-inducible knockout mouse model of mitochondrial transcription factor A (TFAM), a nuclear-encoded protein involved in mitochondrial DNA (mtDNA) maintenance — Tfamfl/flUbcCre-ERT2 (iTfamKO) mice. Systemic TFAM deficiency triggers mitochondrial decline in a myriad of tissues in adult mice. Consequently, iTfamKO mice manifest multiorgan dysfunction including lipodystrophy, sarcopenia, metabolic alterations, kidney failure, neurodegeneration, and locomotor dysregulation, which result in the premature death of these mice. Interestingly, iTfamKO mice display intestinal barrier disruption and gut dysbiosis, with diminished levels of microbiota-derived short-chain fatty acids (SCFAs), such as butyrate. Mice with a deficient proof-reading version of the mtDNA polymerase gamma (mtDNA-mutator mice) phenocopy the dysfunction of the intestinal barrier and bacterial dysbiosis with reduced levels of butyrate, suggesting that different mouse models of mitochondrial dysfunction share insufficient generation of butyrate. Transfer of microbiota from healthy control mice or administration of tributyrin, a butyrate precursor, delay multiple signs of multimorbidity, extending lifespan in iTfamKO mice. Mechanistically, butyrate supplementation recovers epigenetic histone acylation marks that are lost in the intestine of Tfam deficient mice. Overall, our findings highlight the relevance of preserving host-microbiota symbiosis in disorders related to mitochondrial dysfunction., We thank the Oxford Hospitals charity and Lily Foundation “Treatments for Mitochondrial Disease – 2019/20” (J.P.), Fundación Ramón Areces and MINECO through the Centers of Excellence Severo Ochoa Award, and CERCA Programme of the Generalitat de Catalunya (A.V.L.-V.). Funded by the European Union (M.M.). Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. This research was supported by a European Research Council grant ERC-2021-CoG 101044248-Let T Be (M.M.), Comunidad de Madrid (Spain) grant Y2020/BIO-6350 NutriSION-CM synergy (E.C. and M.M.), Spanish Ministerio de Ciencia e Innovación grant PID2022-141169OB-I00 (M.M.), Comunidad de Madrid (Spain) – Universidad Autónoma de Madrid (UAM) grant SI4/PJI/2024-00166 (E.C.), NIH grant R01 DK095782 (G.N.), Ministerio de Ciencia, Innovación y Universidades (Spain) FPU grants FPU19/02576 (M.M.G.H.), FPU24/02492 (P.R.-R.) and FPU20/04066 (J.I.E.-L.), Comunidad de Madrid (Spain) PIPF grant PIPF-2022/SAL-GL-25208 (S.D.-P.), Universidad Autónoma de Madrid FPI-UAM grant (G.S.-H.), and Ministerio de Ciencia, Innovación y Universidades (Spain) Juan de la Cierva-Incorporación grants IJC2018-036850-I (E.G.-R.) and JC2020-044392-I (I.F.-Q.)., Peer reviewed
Proyecto:
EC / HE 101044248
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-141169OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 IJC2018-036850-I
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 IJC2020-044392-I